SCYNEXIS (SCYX)
NASDAQ:SCYX
Want to see SCYX full AI Analyst Report?
Top Page
SCYNEXIS
(NASDAQ:SCYX)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▲(506.06% Upside)
Action:Reiterated
Date:06/01/26
The score is held down primarily by weak financial performance (large losses and continued cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate events and a stronger funding runway provide support, but valuation remains challenged due to ongoing losses.
Positive Factors
Pipeline Expansion - SCY-770 Acquisition
Buying SCY-770 materially diversifies SCYNEXIS beyond antifungals into a high-value orphan nephrology program. Phase 2–ready status, orphan designation, an FDA-endorsed surrogate endpoint and IP protection through 2042 accelerate development optionality and lengthen exclusivity, improving long-term upside versus a single-product antifungal focus.
Negative Factors
Ongoing Cash Burn
Persistent negative operating and free cash flows mean the company depends on external capital to sustain R&D and operations. If clinical timelines slip or milestone triggers fail, dilution risk and funding stress rise, constraining strategic choices and potentially delaying development programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline Expansion - SCY-770 Acquisition
Buying SCY-770 materially diversifies SCYNEXIS beyond antifungals into a high-value orphan nephrology program. Phase 2–ready status, orphan designation, an FDA-endorsed surrogate endpoint and IP protection through 2042 accelerate development optionality and lengthen exclusivity, improving long-term upside versus a single-product antifungal focus.
Read all positive factors
SCYNEXIS (SCYX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.01M
Dividend YieldN/A
Average Volume (3M)612.75K
Price to Earnings (P/E)―
Beta (1Y)1.21
Revenue Growth673.54%
EPS Growth23.14%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-3.58
Shares Outstanding9,930,329
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market Cap0.02
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$32.00Price Target Upside4748.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.99
Revenue Forecast (FY)$1.17M
SCYNEXIS Business Overview & Revenue Model
Company Description
SCYNEXIS, Inc. is a biotechnology firm based in the U.S. dedicated to developing therapies for fungal infections. The company's flagship product, BREXAFEMME (ibrexafungerp tablets), has received approval for the treatment of vulvovaginal candidias...
How the Company Makes Money
SCYNEXIS generates revenue primarily through partnering and commercialization arrangements rather than running a large standalone sales infrastructure. Key revenue streams include: (1) collaboration/licensing revenue such as upfront payments, mile...
SCYNEXIS Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 20.34M | 20.60M | 3.75M | 140.14M | 5.09M | 13.16M |
| Gross Profit | 20.34M | 20.60M | 3.75M | 124.52M | 4.46M | 12.85M |
| EBITDA | -24.52M | -8.44M | -18.58M | 70.89M | -59.91M | -32.91M |
| Net Income | -24.52M | -8.61M | -21.29M | 67.04M | -62.81M | -32.87M |
Balance Sheet | ||||||
| Total Assets | 77.63M | 59.03M | 90.64M | 128.41M | 87.81M | 119.84M |
| Cash, Cash Equivalents and Short-Term Investments | 59.26M | 21.26M | 59.30M | 74.36M | 73.50M | 104.48M |
| Total Debt | 2.06M | 2.17M | 16.27M | 15.08M | 48.60M | 43.63M |
| Total Liabilities | 36.32M | 9.65M | 35.57M | 55.45M | 84.58M | 78.58M |
| Stockholders Equity | 41.31M | 49.38M | 55.08M | 72.96M | 3.23M | 41.26M |
Cash Flow | ||||||
| Free Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.89M | -55.73M |
| Operating Cash Flow | -5.92M | -5.28M | -24.01M | 60.16M | -79.88M | -54.56M |
| Investing Cash Flow | 11.34M | 24.31M | 6.15M | -34.88M | -27.39M | -1.17M |
| Financing Cash Flow | 23.95M | -14.17M | -139.00K | -36.72M | 48.60M | 67.12M |
SCYNEXIS Technical Analysis
Negative
0.66
Price Trends
6.69
Negative
6.56
Negative
6.29
Negative
Market Momentum
-0.68
Positive
28.70
Positive
4.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCYX, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 5.11, below the 50-day MA of 6.69, and below the 200-day MA of 6.29, indicating a bearish trend. The MACD of -0.68 indicates Positive momentum. The RSI at 28.70 is Positive, neither overbought nor oversold. The STOCH value of 4.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCYX.
SCYNEXIS Risk Analysis
SCYNEXIS disclosed 44 risk factors in its most recent earnings report. SCYNEXIS reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SCYNEXIS Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $83.91M | -11.58 | -28.75% | ― | 2.08% | -106.57% | |
54 Neutral | $25.46M | 142.25 | 0.27% | ― | 82.13% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $24.66M | -4.56 | -15.41% | ― | -30.75% | -1056.69% | |
47 Neutral | $23.08M | -0.66 | -107.16% | ― | -18.24% | -2264.65% | |
46 Neutral | $42.01M | -1.10 | -57.16% | ― | 673.54% | 23.14% | |
42 Neutral | $1.45M | -14.53 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
SCYX
SCYNEXIS
4.23
-2.05
-32.64%
RMTI
Rockwell Med
0.62
-0.33
-34.32%
TXMD
TherapeuticsMD
2.20
1.12
103.70%
AYTU
Aytu BioScience
2.15
0.17
8.59%
CPIX
Cumberland Pharmaceuticals
5.60
0.12
2.19%
IMCC
IM Cannabis Corp
0.23
-2.03
-89.73%
SCYNEXIS Corporate Events
Shareholder MeetingsStock Split
SCYNEXIS Stockholders Approve One-for-Eight Reverse Split
Neutral
May 22, 2026
On May 19, 2026, SCYNEXIS stockholders approved an amendment to the company’s certificate of incorporation authorizing a reverse stock split in a range between 1-for-5 and 1-for-10 and a reduction in authorized shares, with 44,826,378 votes ...
Executive/Board Changes
SCYNEXIS Director Steven Gilman Announces Board Retirement
Neutral
Apr 20, 2026
On April 16, 2026, SCYNEXIS director Steven C. Gilman notified the company that he will retire from the Board and will not stand for reelection at the 2026 annual meeting of stockholders. His term will end at the conclusion of that meeting, at whi...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
Positive
Mar 31, 2026
On March 31, 2026, SCYNEXIS held a conference call to discuss a strategic asset acquisition and broader corporate update, highlighting its purchase of global rights to SCY-770 from French biotech Poxel. The company detailed that SCY-770 is a well-...
Business Operations and StrategyM&A Transactions
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline
Positive
Mar 31, 2026
On March 30, 2026, SCYNEXIS entered an asset purchase agreement to acquire Poxel SA’s direct AMP kinase activator program, including the clinical-stage compound PXL-770, now renamed SCY-770, and all related intellectual property, regulatory ...
Business Operations and StrategyPrivate Placements and Financing
SCYNEXIS Raises $40 Million in Strategic Private Placement
Positive
Mar 31, 2026
On March 30, 2026, SCYNEXIS agreed to raise approximately $40 million in gross proceeds through a private placement of 34.75 million common shares, 8.75 million pre-funded warrants and 43.5 million common warrants to new and existing institutional...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.